Western Australian Drug Evaluation Panel (WADEP)
The Western Australian Drug Evaluation Panel (WADEP), established in August 2002, is tasked with oversight of the Statewide Medicines Formulary (SMF).
The vision of the Western Australian Statewide Medicines Formulary (SMF) is to deliver optimal patient outcomes in an equitable manner through a single list of approved medicines for the WA health system; evaluated, implemented and managed in a statewide approach.
In this role, WADEP make decisions on medicines available for prescribing in the WA health service based on clinical efficacy, cost-effectiveness, evidence of need, patient safety and equity. The Panel works closely with hospital Drugs and Therapeutics Committees (DTCs), lead clinicians and expert advisors, pharmacy departments and those making applications to the SMF to facilitate a robust, fair and transparent review process.
Other responsibilities of the Panel include facilitating the development of best-practice standards and guidelines for medicines and making recommendations to State and national bodies on medicines use, governance, cost and cost-effectiveness.
Membership of WADEP and terms of reference
Members of WADEP may be drawn from Metropolitan Health Services, WA Country Health Service, private and public health sectors, health administration and academia and are governed by terms of reference. WADEP may co-opt additional members for specialist expertise and advice as required.
More information
WADEP
Medicines and Technology Unit
Patient Safety and Clinical Quality,
Clinical Excellence Division
Address: 189 Royal Street
EAST PERTH WA 6004
Phone: 61 8 9222 2109
Email: WADEP@health.wa.gov.au
Last reviewed: 30-10-2019
Produced by
Patient Safety and Clinical Quality